1 Introduction CAR T cell-mediated deep B cell depletion has emerged as a promising therapeutic strategy across a broad spectrum of autoantibody-driven autoimmune disorders, including diseases of the neurological spectrum [1, 2]. More recently, attention has expanded toward primary inflammatory disorders of the central nervous system (CNS), such as multiple sclerosis (MS), in which compartmentalized, tissue-resident immune responses are thought to contribute to disease progression [3, 4].